Summary & Overview
HCPCS J0180: Injection, agalsidase beta, 1 mg
HCPCS Level II code J0180 represents a 1 mg injection of agalsidase beta, an enzyme replacement therapy administered via intravenous infusion. Nationally, this code matters because it identifies billing for a specialized biologic used in rare metabolic conditions, carries implications for coverage policy, prior authorization, and site-of-care considerations, and often drives significant pharmacy and infusion reimbursement activity.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of typical coverage and payment contexts, benchmarks for utilization and cost where available, clinical context for use of agalsidase beta, and relevant administrative considerations such as common modifiers and billing practice guidance. The publication summarizes payer approaches to authorizations and site-of-service distinctions, highlights areas where payment policy updates commonly occur, and provides practical billing references for coding and claims submission.
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes is noted where applicable.
Billing Code Overview
HCPCS Level II code J0180 denotes Injection, agalsidase beta, 1 mg. This code describes a biologic enzyme replacement therapy administered by injection for patients requiring intravenous infusion of agalsidase beta. The service type is an injectable biologic medication infused intravenously, and the typical site of service is an outpatient infusion center or hospital outpatient department.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with confirmed Fabry disease receiving maintenance enzyme replacement therapy with agalsidase beta. The patient arrives to an outpatient infusion center or hospital outpatient infusion suite for intravenous administration of J0180 (agalsidase beta, 1 mg). Pre-infusion nursing assessment includes vital signs, review of recent labs (renal function, liver enzymes), medication reconciliation, and allergy review. The ordered dose is calculated based on the patient’s weight (usually mg/kg) and pharmacy prepares the appropriate number of milligrams; billing uses units of J0180 per 1 mg. An infusion nurse establishes IV access, administers infusion per product monograph with appropriate infusion rate escalation and infusion-related reaction monitoring, and documents start/stop times and any medications given for adverse events (e.g., antihistamines, corticosteroids). Post-infusion observation ensures hemodynamic stability before discharge. Typical sites of service are outpatient infusion center, hospital outpatient department, or physician office capable of supervised IV biologic administration. Payers commonly involved include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare according to contractual coverage policies for enzyme replacement therapy.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW |